Analyst Price Targets — BWAY
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 31, 2026 10:06 am | Raghuram Selvaraju | H.C. Wainwright | $19.00 | $14.30 | TheFly | Brainsway price target raised to $19 from $17 at H.C. Wainwright |
| August 12, 2026 5:02 pm | Sam Eiber | BTIG | $20.00 | $16.60 | StreetInsider | Brainsway (BWAY) PT Raised to $20 at BTIG |
| July 20, 2026 9:59 am | — | BTIG | $18.00 | $15.73 | TheFly | Brainsway initiated with a Buy at BTIG |
| July 17, 2026 11:11 am | Raghuram Selvaraju | H.C. Wainwright | $14.00 | $14.84 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Brainsway (BWAY) |
| May 26, 2026 10:15 am | Raghuram Selvaraju | H.C. Wainwright | $17.00 | $15.10 | TheFly | Brainsway price target raised to $17 from $15 at H.C. Wainwright |
| January 26, 2026 11:07 am | — | H.C. Wainwright | $15.00 | $11.52 | TheFly | Brainsway price target raised to $30 from $24 at H.C. Wainwright |
| January 22, 2026 2:01 pm | — | Northland Securities | $15.00 | $12.30 | TheFly | Brainsway price target raised to $30 from $23 at Northland |
| December 8, 2025 11:15 am | Raghuram Selvaraju | H.C. Wainwright | $12.00 | $8.64 | TheFly | Brainsway price target raised to $24 from $18 at H.C. Wainwright |
| August 7, 2024 6:14 am | Raghuram Selvaraju | H.C. Wainwright | $8.00 | $3.45 | TheFly | Brainsway price target raised to $16 from $15 at H.C. Wainwright |
| May 9, 2024 7:36 am | Steven Lichtman | Oppenheimer | $5.50 | $2.85 | StreetInsider | Brainsway (BWAY) PT Raised to $11 at Oppenheimer |
Latest News for BWAY
Brainsway (NASDAQ: BWAY - Get Free Report) and Green Thumb Industries (OTCMKTS:GTBIF - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability. Profitability This table compares Brainsway and Green
The mean of analysts' price targets for Brainsway (BWAY) points to a 30.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Brainsway (BWAY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Brainsway Ltd. Sponsored ADR (NASDAQ: BWAY - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the seven research firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 1-year target
Brainsway NASDAQ: BWAY reported second-quarter revenue growth of 35% and raised its full-year 2026 revenue outlook, citing continued demand for its Deep TMS systems, expanding reimbursement for its accelerated SWIFT treatment protocol and growth in its installed base.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BWAY.
U.S. House Trading
No House trades found for BWAY.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.